Kinled is a company that retains the assets of the Anglo-Austrian Aisher Family through direct investments in innovative businesses in the Life Science and Digital Technology sectors.
Today, in life sciences, we have a laser focus on innovation in the biomedical technology, medical devices, biopharmaceuticals, and healthcare services sectors, which represent over 50% of our portfolio. In digital technologies, we invest in SaaS-enabled networks and marketplaces, where technology can democratize markets and provide consumers with a greater choice of services. In fintech, we invest in companies that use technology to challenge the traditionally established institutions by providing superior service in embedded payment platforms, insurance, real estate, lending, and banking.
People
- Daniela Siebenthal, Director
You last contacted this investor on .